I am an Associate Professor of Medicine (Hematology, Oncology, and Transplantation) at Fred Hutch with clinical trial and computational expertise. I have a broad background with a Master of Science in Clinical Investigation combined with computational sciences training, including a PhD in evolutionary models of aging and a KL2 career development award focused on microbiome bioinformatics. I leverage my clinical and computational expertise to make cancer treatment safer by improving supportive care. I characterize microbiota disruptions in patients with cancer, investigate their clinical significance, and test microbiota restorative therapeutics to improve clinical outcomes. Recently, I led the largest clinical trial of FMT in allogeneic stem cell transplant recipients to date. We used findings from this trial to design the proposed randomized placebo-controlled phase 2 trial of third-party FMT to prevent aGVHD after transplantation.

Armin Rashidi MD, PhD
Fred Hutchinson Cancer Center
Seattle, Washington
United States
Project Title
Fecal microbiota transplantation to prevent acute GVHD after allogeneic stem cell transplantation
Program
Academic Clinical Trials Program (ACT)